Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease

NCT00414622 is registered in ClinicalTrials.gov with CoMentis as lead sponsor.

NCT NCT00414622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00414622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease
Lead sponsor
CoMentis
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2006
Completion date
April 30, 2007
Enrollment
60
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease